This week, the overall grades of 21 Health Care Equipment & Supplies stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This is a rough week for STERIS Plc (STE). The company’s rating falls to D from the previous week’s C. STERIS Plc provides products and services related to infection prevention and surgical procedures. For more information, get Portfolio Grader’s complete analysis of STE stock.
This week, Neogen Corporation (NEOG) drops from a C to a D rating. Neogen Corporation develops and markets products and services dedicated to food and animal safety. For more information, get Portfolio Grader’s complete analysis of NEOG stock.
Natus Medical Incorporated (BABY) declines this week from a C to a D. Natus Medical Incorporated is a medical device company that develops, manufactures, and markets screening products. For more information, get Portfolio Grader’s complete analysis of BABY stock.
Orthofix International NV (OFIX) earns a D this week, moving down from last week’s grade of C. Orthofix International NV is a global medical device company offering a line of surgical and non-surgical products mainly in the spine, orthopedics, sports medicine and vascular market sectors. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of OFIX stock.
Globus Medical, Inc. Class A’s (GMED) rating weakens this week, dropping to a D versus last week’s C. Globus Medical, Inc. Class A focuses on the design, development, and commercialization of products that promote healing in patients with spine disorders. For more information, get Portfolio Grader’s complete analysis of GMED stock.
Quidel Corporation (QDEL) slips from a B to a D this week. Quidel Corporation discovers, develops, manufactures, and markets rapid diagnostic products for point-of-care detection of human medical conditions and illnesses. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of QDEL stock.
Slipping from a C to a D rating, Cutera, Inc. (CUTR) takes a hit this week. Cutera, Inc. is a global provider of laser and other light-based aesthetic systems for practitioners worldwide. For more information, get Portfolio Grader’s complete analysis of CUTR stock.
Novadaq Technologies Inc. (NVDQ) is having a tough week. The company’s rating falls from a C to a D. Novadaq Technologies Inc. develops and commercializes medical devices based on its proprietary imaging platform for the diagnosis and treatment of human vascular and opthalmic diseases and conditions. The company also gets F’s in earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of NVDQ stock.
Syneron Medical Ltd (ELOS) experiences a ratings drop this week, going from last week’s C to a D. Syneron Medical Ltd designs, develops, and markets aesthetic medical products based on proprietary Electro-Optical Synergy technologies. The company also gets F’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of ELOS stock.
This week, Novocure Ltd.’s (NVCR) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVCR stock.
CytoSorbents Corporation (CTSO) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in earnings growth, earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of CTSO stock.
Invuity Inc (IVTY) is having a tough week. The company’s rating falls from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of IVTY stock.
Cerus Corporation (CERS) experiences a ratings drop this week, going from last week’s C to a D. Cerus Corporation is a biomedical products company engaged in the development and commercialization of the INTERCEPT Blood System. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of CERS stock.
Accuray Incorporated (ARAY) slips from a C to a F this week. Accuray Incorporated designs, develops, and sells medical radiation systems for the treatment of tumors anywhere in the body. The company also gets F’s in earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of ARAY stock.
Quotient Ltd. (QTNT) declines this week from a D to a F. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of QTNT stock.
Ekso Bionics Holdings, Inc. (EKSO) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in sales growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EKSO stock.
This week, InVivo Therapeutics Corporation (NVIV) drops from a C to a D rating. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVIV stock.
ViewRay, Inc. (VRAY) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of VRAY stock.
This week, ReWalk Robotics Ltd.’s (RWLK) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of RWLK stock.
This is a rough week for Tandem Diabetes Care, Inc. (TNDM). The company’s rating falls to F from the previous week’s C. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of TNDM stock.
Bellerophon Therapeutics, Inc.’s (BLPH) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of BLPH stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
